Galmed Pharmaceuticals’ Aramchol Abstract Accepted for HEP-DART 2025 Presentation

Galmed Pharmaceuticals ( (GLMD) ) has provided an update.

On December 8, 2025, Galmed Pharmaceuticals announced the acceptance of a late-breaking abstract for its lead drug candidate, Aramchol, to be presented at the HEP-DART 2025 meeting. The abstract highlights the potential of Aramchol in combination with regorafenib to enhance treatment efficacy in hepatocellular carcinoma and other gastrointestinal cancers. This development has led to the initiation of a Phase 1/2 clinical trial by VCU Massey Comprehensive Cancer Center, with enrollment planned for 2026. The successful presentation and subsequent clinical trial could significantly expand Galmed’s oncology pipeline and create value for stakeholders.

Spark’s Take on GLMD Stock

According to Spark, TipRanks’ AI Analyst, GLMD is a Underperform.

Galmed Pharmaceuticals faces significant financial challenges, with no revenue and continuous losses, which heavily impact its stock score. Poor technical indicators and negative valuation metrics further weigh down the score. The strong equity position offers some support but is overshadowed by the lack of operational efficiency and profitability.

To see Spark’s full report on GLMD stock, click here.

More about Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutics for liver, cardiometabolic diseases, and gastrointestinal oncological conditions. The company is primarily known for its lead drug candidate, Aramchol, which is being developed for the treatment of liver diseases and certain oncological indications. Galmed is actively working to expand its product pipeline to include cardiometabolic indications and other innovative drug candidates.

Average Trading Volume: 2,053,006

Technical Sentiment Signal: Sell

Current Market Cap: $6.14M

For an in-depth examination of GLMD stock, go to TipRanks’ Overview page.